{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:56:22Z","timestamp":1763600182949,"version":"3.41.2"},"reference-count":76,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>5-aminosalicylates (5-ASAs) are commonly used in non-surgical patients with Crohn\u2019s disease (CD), especially in mild-to-moderate disease, despite current guidelines against their use. Despite this, the evidence regarding their efficacy is mixed, with conflicting findings in systematic reviews (SRs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>We conducted an overview of reviews (umbrella review) to consolidate existing knowledge from published SRs on using 5-ASAs in patients with active or quiescent CD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We systematically searched for relevant SRs published in English until July 6, 2024, summarizing data on 5-ASAs used in induction, maintenance, or withdrawal trials of CD. We also searched for placebo-controlled RCTs of 5-ASAs published after 2015.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eight SRs met our inclusion criteria, with the number of included RCTs of 5-ASAs in CD ranging from 2 to 22. Two were network meta-analyses (NMA); 4 were Cochrane SRs. SRs found no evidence of benefit for oral 5-ASAs over placebo for maintaining medically induced remission. The latest NMA in 2017, including 22 RCTs for induction of remission, suggested that high-dose mesalamine (\u2265\u20052.4\u00a0g) was more effective than placebo, though ranking lower than systemic corticosteroid and high-dose budesonide. No placebo-controlled RCT of 5-ASAs was published after 2015, only the ongoing STATIC trial is investigating the withdrawal of 5-ASAs in patients with quiescent CD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This overview of SRs suggests that the evidence does not support the use of 5-ASAs for maintaining medically induced remission. However, high-dose mesalamine may be considered for inducing remission in selected patients with mild luminal CD who prefer to avoid steroids.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf069","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T08:49:00Z","timestamp":1745225340000},"source":"Crossref","is-referenced-by-count":1,"title":["5-Aminosalicylates for non-surgical patients with active or quiescent Crohn\u2019s disease: an overview of systematic reviews (umbrella review)"],"prefix":"10.1093","volume":"19","author":[{"given":"Abdulaziz","family":"Alajmi","sequence":"first","affiliation":[{"name":"Department of Medicine, London Health Science Center , London, Ontario ,","place":["Canada"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4374-3042","authenticated-orcid":false,"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Medicine, London Health Science Center , London, Ontario ,","place":["Canada"]},{"name":"Department of Medine, Western University , London, Ontario ,","place":["Canada"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-6778","authenticated-orcid":false,"given":"Virginia","family":"Solitano","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy, IRCCS Hospital San Raffaele and University Vita-Salute San Raffaele , Milan ,","place":["Italy"]},{"name":"Department of Epidemiology and Biostatistics, Western University , London, Ontario ,","place":["Canada"]}]},{"given":"Daniel Eli Cohen","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"Western University , London, Ontario ,","place":["Canada"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-0139","authenticated-orcid":false,"given":"Maria Manuela","family":"Estevinho","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto , Porto ,","place":["Portugal"]},{"name":"Department of Gastroenterology, Unidade Local de Sa\u00fade Gaia Espinho , Vila Nova de Gaia ,","place":["Portugal"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto , Porto ,","place":["Portugal"]},{"name":"Department of Gastroenterology, Unidade Local de Sa\u00fade de S\u00e3o Jo\u00e3o , Porto ,","place":["Portugal"]}]},{"given":"Olga Maria","family":"Nardone","sequence":"additional","affiliation":[{"name":"Gastroenterology, Department of Public Health, University Federico II of Naples , Naples ,","place":["Italy"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0033","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Department of Medicine, London Health Science Center , London, Ontario ,","place":["Canada"]},{"name":"Department of Medine, Western University , London, Ontario ,","place":["Canada"]},{"name":"Department of Epidemiology and Biostatistics, Western University , London, Ontario ,","place":["Canada"]}]}],"member":"286","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"2025060311002637900_CIT0001","doi-asserted-by":"crossref","first-page":"12445","DOI":"10.3390\/ijms232012445","article-title":"Etiology of IBD-is it still a mystery","volume":"23","author":"Kofla-Dlubacz","year":"2022","journal-title":"Int J Mol Sci ."},{"key":"2025060311002637900_CIT0002","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.cgh.2022.06.030","article-title":"Global hospitalization trends for Crohn\u2019s disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses","volume":"21","author":"Buie","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025060311002637900_CIT0003","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2036.2004.02048.x","article-title":"Review article: aminosalicylates in inflammatory bowel disease","volume":"20","author":"Hanauer","year":"2004","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311002637900_CIT0004","first-page":"500","article-title":"The use of 5-aminosalicylates in Crohn\u2019s disease: a retrospective study using the UK clinical practice research datalink","volume":"33","author":"Hart","year":"2020","journal-title":"Ann Gastroenterol."},{"key":"2025060311002637900_CIT0005","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/ibd\/izaa127","article-title":"Trends of 5-aminosalicylate medication use in patients with crohn disease","volume":"27","author":"Noureldin","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2025060311002637900_CIT0006","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology."},{"key":"2025060311002637900_CIT0007","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis."},{"key":"2025060311002637900_CIT0008","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut."},{"key":"2025060311002637900_CIT0009","first-page":"CD008414","article-title":"Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn\u2019s disease","volume":"6","author":"Gjuladin-Hellon","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"key":"2025060311002637900_CIT0010","first-page":"i1410","article-title":"Efficacy and safety of medical therapies for maintenance of surgically induced remission in Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"18","author":"Sinopoulou","year":"2024","journal-title":"J Crohns Colitis."},{"key":"2025060311002637900_CIT0011","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000518865","article-title":"5-Aminosalicylic acid chemoprevention in inflammatory bowel diseases: is it necessary in the age of biologics and small molecules","volume":"7","author":"Herfarth","year":"2022","journal-title":"Inflamm Intest Dis."},{"key":"2025060311002637900_CIT0012","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/2050640620945949","article-title":"The use of 5-aminosalicylate for patients with Crohn\u2019s disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study","volume":"8","author":"Burisch","year":"2020","journal-title":"United European Gastroenterol J."},{"key":"2025060311002637900_CIT0013","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2025060311002637900_CIT0014","article-title":"Chapter V: overviews of reviews","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023)","author":"Pollock","year":"2023"},{"key":"2025060311002637900_CIT0015","doi-asserted-by":"crossref","DOI":"10.46658\/JBIMES-24-08","article-title":"Umbrella reviews (2020)","volume-title":"JBI Manual for Evidence Synthesis.","author":"Aromataris","year":"2024"},{"key":"2025060311002637900_CIT0016","doi-asserted-by":"crossref","first-page":"e070849","DOI":"10.1136\/bmj-2022-070849","article-title":"Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement","volume":"378","author":"Gates","year":"2022","journal-title":"BMJ"},{"key":"2025060311002637900_CIT0017","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025060311002637900_CIT0018","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/ueg2.12636","article-title":"Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta-analysis of randomized controlled trials","volume":"12","author":"Estevinho","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"2025060311002637900_CIT0019","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ."},{"key":"2025060311002637900_CIT0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13643-023-02388-x","article-title":"Methodological review of NMA bias concepts provides groundwork for the development of a list of concepts for potential inclusion in a new risk of bias tool for network meta-analysis (RoB NMA Tool)","volume":"13","author":"Lunny","year":"2024","journal-title":"Syst Rev"},{"volume-title":"Stopping Aminosalicylate Therapy in Inactive Crohn\u2019s Disease. Stopping Aminosalicylate Therapy in Inactive Crohn\u2019s Disease (STATIC) Study: a Randomized, Open-label, Non-inferiority Trial;","year":"2017","author":"NCT03261206","key":"2025060311002637900_CIT0021"},{"key":"2025060311002637900_CIT0022","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MIB.0000000000001023","article-title":"Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn\u2019s disease: a bayesian network meta-analysis","volume":"23","author":"Coward","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2025060311002637900_CIT0023","first-page":"CD000545","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn\u2019s disease","volume":"10","author":"Chande","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025060311002637900_CIT0024","first-page":"CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn\u2019s disease","volume":"7","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025060311002637900_CIT0025","first-page":"CD003715","article-title":"Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn\u2019s disease","volume":"9","author":"Akobeng","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025060311002637900_CIT0026","first-page":"CD000067","article-title":"Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn\u2019s disease","volume":"2015","author":"Chande","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025060311002637900_CIT0027","first-page":"1927","article-title":"Azathioprine\/6-mercaptopurine versus 5-aminosalicylic for treatment of inflammatory bowel disease","volume":"10","author":"Chen","year":"2017","journal-title":"Int J Clin Exp Med."},{"key":"2025060311002637900_CIT0028","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/apt.13190","article-title":"Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn\u2019s disease","volume":"41","author":"Moja","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311002637900_CIT0029","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ajg.2011.71","article-title":"Efficacy of 5-aminosalicylates in Crohn\u2019s disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol."},{"key":"2025060311002637900_CIT0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/gut.18.1.69","article-title":"Sulphasalazine in asymptomatic Crohn\u2019s disease. A multicentre trial","volume":"18","author":"Lennard-Jones","year":"1977","journal-title":"Gut."},{"key":"2025060311002637900_CIT0031","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National cooperative Crohn\u2019s disease study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology."},{"key":"2025060311002637900_CIT0032","doi-asserted-by":"crossref","first-page":"716","DOI":"10.12659\/MSM.889196","article-title":"Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn\u2019s disease patients","volume":"19","author":"de Souza","year":"2013","journal-title":"Med Sci Monit."},{"year":"2012","author":"PEACH","key":"2025060311002637900_CIT0033"},{"key":"2025060311002637900_CIT0034","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1053\/j.gastro.2010.11.004","article-title":"Budesonide 9\u00a0mg is at least as effective as mesalamine 4.5\u00a0g in patients with mildly to moderately active Crohn\u2019s disease","volume":"140","author":"Tromm","year":"2011","journal-title":"Gastroenterology."},{"key":"2025060311002637900_CIT0035","first-page":"617","article-title":"Unpublished-personal communication from Ford 2011 Systematic review (Reference 29","volume-title":"Am J Gastroenterol.","author":"Crohns-II-Trial","year":"2004"},{"key":"2025060311002637900_CIT0036","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","article-title":"Oral Pentasa in the treatment of active Crohn\u2019s disease: a meta-analysis of double-blind, placebo-controlled trials 2004","volume":"2","author":"Hanauer","year":"1997","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025060311002637900_CIT0037","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00042737-200012110-00010","article-title":"6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease","volume":"12","author":"Mate-Jimenez","year":"2000","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"2025060311002637900_CIT0038","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0016-5085(99)70172-1","article-title":"Mesalamine in the treatment of mild to moderate active Crohn\u2019s ileitis: results of a randomized, multicenter trial","volume":"116","author":"Prantera","year":"1999","journal-title":"Gastroenterology."},{"key":"2025060311002637900_CIT0039","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJM199808063390603","article-title":"A comparison of budesonide and mesalamine for active Crohn\u2019s disease. International Budesonide-Mesalamine Study Group","volume":"339","author":"Thomsen","year":"1998","journal-title":"N Engl J Med."},{"key":"2025060311002637900_CIT0040","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00054725-199512000-00001","article-title":"A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn\u2019s disease","volume":"1","author":"Wright","year":"1995","journal-title":"Inflamm Bowel Dis."},{"key":"2025060311002637900_CIT0041","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00004836-199412000-00003","article-title":"A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn\u2019s colitis and ileocolitis","volume":"19","author":"Tremaine","year":"1994","journal-title":"J Clin Gastroenterol."},{"key":"2025060311002637900_CIT0042","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/0016-5085(94)90210-0","article-title":"Second trial of mesalamine therapy in the treatment of active Crohn\u2019s disease","volume":"107","author":"Singleton","year":"1994","journal-title":"Gastroenterology."},{"key":"2025060311002637900_CIT0043","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0016-5085(93)90337-C","article-title":"Mesalamine capsules for the treatment of active Crohn\u2019s disease: results of a 16-week trial. Pentasa Crohn\u2019s Disease Study Group","volume":"104","author":"Singleton","year":"1993","journal-title":"Gastroenterology."},{"key":"2025060311002637900_CIT0044","first-page":"452","article-title":"Oral 5-ASA versus prednisone in short term treatment of Crohn\u2032s disease: a multicentre controlled trial","volume":"4","author":"Martin","year":"1990","journal-title":"Can J Gastroenterol Hepatol."},{"key":"2025060311002637900_CIT0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000200228","article-title":"Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn\u2019s disease","volume":"45","author":"Mahida","year":"1990","journal-title":"Digestion."},{"key":"2025060311002637900_CIT0046","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3109\/00365528708991929","article-title":"5-Aminosalicylic acid in the treatment of Crohn\u2019s disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa","volume":"22","author":"Rasmussen","year":"1987","journal-title":"Scand J Gastroenterol."},{"key":"2025060311002637900_CIT0047","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn\u2019s Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology."},{"key":"2025060311002637900_CIT0048","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.22.5.404","article-title":"Effect of sulphasalazine in patients with active Crohn\u2019s disease: a controlled double-blind study","volume":"22","author":"Van Hees","year":"1981","journal-title":"Gut."},{"key":"2025060311002637900_CIT0049","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-114-6-445","article-title":"Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial","volume":"114","author":"Rijk","year":"1991","journal-title":"Ann Intern Med."},{"key":"2025060311002637900_CIT0050","first-page":"260563","article-title":"Oral 5-aminosalicyclic acid versus 6-methylprednisolone in active Crohn\u2032s disease","volume":"4","author":"Sch\u00f6lmerich","year":"1990","journal-title":"Can J Gastroenterol Hepatol."},{"key":"2025060311002637900_CIT0051","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000199279","article-title":"Effect of a slow-release 5\u2019-aminosalicylic acid preparation on disease activity in Crohn\u2019s disease","volume":"33","author":"Saverymuttu","year":"1986","journal-title":"Digestion."},{"key":"2025060311002637900_CIT0052","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1055\/s-2008-1068828","article-title":"[Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid]","volume":"110","author":"Maier","year":"1985","journal-title":"Dtsch Med Wochenschr."},{"key":"2025060311002637900_CIT0053","first-page":"581","article-title":"Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn\u2019s ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group","volume":"33","author":"Gross","year":"1995","journal-title":"Z Gastroenterol."},{"key":"2025060311002637900_CIT0054","first-page":"13","article-title":"Clinical efficacy of oral mesalazine in Crohn\u2019s disease","volume":"4","author":"Maier","year":"1990","journal-title":"Can J Gastroenterol Hepatol."},{"key":"2025060311002637900_CIT0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.gcb.2008.07.007","article-title":"Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn\u2019s disease: a multicenter, double-blind, randomized, placebo-controlled trial","volume":"33","author":"Cezard","year":"2009","journal-title":"Gastroenterol Clin Biol."},{"key":"2025060311002637900_CIT0056","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/cgh.2003.50015","article-title":"Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn\u2019s disease","volume":"1","author":"Mantzaris","year":"2003","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025060311002637900_CIT0057","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/gut.49.4.552","article-title":"Olsalazine is not superior to placebo in maintaining remission of inactive Crohn\u2019s colitis and ileocolitis: a double blind, parallel, randomised, multicentre study","volume":"49","author":"Mahmud","year":"2001","journal-title":"Gut."},{"key":"2025060311002637900_CIT0058","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0016-5085(97)70117-3","article-title":"A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn\u2019s disease. The Canadian Mesalamine for Remission of Crohn\u2019s Disease Study Group","volume":"112","author":"Sutherland","year":"1997","journal-title":"Gastroenterology."},{"key":"2025060311002637900_CIT0059","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1365-2036.1997.00212.x","article-title":"Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn\u2019s disease","volume":"11","author":"de Franchis","year":"1997","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311002637900_CIT0060","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1053\/gast.1996.v110.pm8608877","article-title":"Mesalamine in Crohn\u2019s disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d\u2019Etudes Therapeutiques des Affections Inflammatoires Digestives","volume":"110","author":"Modigliani","year":"1996","journal-title":"Gastroenterology."},{"key":"2025060311002637900_CIT0061","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2036.1995.tb00438.x","article-title":"Mesalazine (Mesasal\/Claversal) 1.5\u00a0g b.d. vs. placebo in the maintenance of remission of patients with Crohn\u2019s disease","volume":"9","author":"Thomson","year":"1995","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311002637900_CIT0062","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00004836-199504000-00008","article-title":"A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn\u2019s disease in remission","volume":"20","author":"Arber","year":"1995","journal-title":"J Clin Gastroenterol."},{"key":"2025060311002637900_CIT0063","first-page":"133","article-title":"Long-term therapy with 5-aminosalicylic acid in Crohn\u2019s disease: is it useful? Our four years experience","volume":"14","author":"Bresci","year":"1994","journal-title":"Int J Clin Pharmacol Res."},{"key":"2025060311002637900_CIT0064","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0016-5085(93)90411-5","article-title":"Oral mesalamine (Pentasa) as maintenance treatment in Crohn\u2019s disease: a multicenter placebo-controlled study. The Groupe d\u2019Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID)","volume":"104","author":"Gendre","year":"1993","journal-title":"Gastroenterology."},{"key":"2025060311002637900_CIT0065","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0016-5085(92)90822-G","article-title":"Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn\u2019s disease","volume":"103","author":"Prantera","year":"1992","journal-title":"Gastroenterology."},{"key":"2025060311002637900_CIT0066","first-page":"68","article-title":"Mesalazine (Pentasa) as prophylaxis in Crohn\u2019s disease. A multicenter, controlled trial","volume":"26","author":"Bondesen","year":"1991","journal-title":"Scand J Gastroenterol."},{"key":"2025060311002637900_CIT0067","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2036.1990.tb00449.x","article-title":"Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn\u2019s disease. International Mesalazine Study Group","volume":"4","author":"IMSG","year":"1990","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311002637900_CIT0068","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/0016-5085(79)90386-X","article-title":"National cooperative Crohn\u2019s disease study: adverse reactions to study drugs","volume":"77","author":"Singleton","year":"1979","journal-title":"Gastroenterology."},{"key":"2025060311002637900_CIT0069","first-page":"71A","article-title":"New oral preparations for maintenance therapy in Crohn\u2019s disease","volume":"2","author":"Wellmann","year":"1988","journal-title":"Can J Gastroenterol."},{"key":"2025060311002637900_CIT0070","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ."},{"key":"2025060311002637900_CIT0071","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"2025060311002637900_CIT0072","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ."},{"key":"2025060311002637900_CIT0073","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2025060311002637900_CIT0074","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2025060311002637900_CIT0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn\u2019s and colitis organisation topical review on treatment withdrawal [\u2018Exit Strategies\u2019] in inflammatory bowel disease","volume":"12","author":"Doherty","year":"2018","journal-title":"J Crohns Colitis."},{"key":"2025060311002637900_CIT0076","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/psb.952","article-title":"5-ASAs in Crohn\u2019s disease: are they any better than placebo","volume":"23","author":"Ray","year":"2012","journal-title":"Prescriber."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf069\/62959120\/jjaf069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjaf069\/62959120\/jjaf069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjaf069\/62959120\/jjaf069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:02:32Z","timestamp":1748962952000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf069\/8116756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf069","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"type":"print","value":"1873-9946"},{"type":"electronic","value":"1876-4479"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,21]]},"article-number":"jjaf069"}}